Business
Immuno-Oncology Summit Europe Presentation
Immuno-Oncology Summit Europe Presentation.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \n \n 16 May 2022\n \n \n \n \n \n \n Hemogenyx Pharmaceuticals plc\n \n \n \n \n (\"Hemogenyx Pharmaceuticals\" or the \"Company\")\n \n \n \n Immuno-Oncology Summit Europe Presentation\n \n \n \n \n \n \n \n \n \n Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce its participation in the Immuno-Oncology Summit Europe 2022, at which Dr Vladislav Sandler will make a presentation entitled \"\n Anti-FLT3 CAR-T and Bispecific Antibody Therapies for Effective Elimination of AML and Conditioning for Hematopoietic Stem Cell Transplantation\"\n . The conference assembles a wide range of thought leaders from both academia and industry and will be held at Hilton London Canary Wharf on 23-25 May 2022.\n \n \n \n \n \n The Immuno-Oncology Summit is an important and influential conference, and Hemogenyx Pharmaceuticals is very pleased to be invited to make its presentation. This underlines the potential of the Company's product candidates and gives it the opportunity to draw the attention of a wide range of industry and academic leaders in the field.\n \n \n \n \n \n As part of his presentation, Dr Sandler will discuss the properties and major advantages of two of the Company's product candidates, its CDX bispecific antibody and HEMO-CAR-T, as potential treatments for relapsed or refractory acute myeloid leukemia and conditioning of patients for bone marrow transplants.\n \n \n \n \n \n Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: \"Our presentation at the Immuno-Oncology Summit Europe 2022 provides the Company with a great opportunity to inform the scientific, industrial and investment communities about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the development of medicines for the treatment of blood and autoimmune diseases.\n \n \"\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Enquiries:\n \n \n \n \n \n \n \n \n \n \n \n \n \n Hemogenyx Pharmaceuticals plc\n \n \n \n \n \n \n https://hemogenyx.com\n \n \n \n \n \n \n \n Dr Vladislav Sandler, Chief Executive Officer & Co-Founder\n \n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n Peter Redmond, Director\n \n \n \n \n \n peter.redmond@hem...